Kathryn Dunne

Kathryn Dunne

Auto-generated profile, based on publicly available information

Kathryn Dunne

Ralph Lauren Centre for Breast Cancer Research, London, UNITED KINGDOM

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MCMaria Coakley
Maria Coakley
GVGuillermo Villacampa
Guillermo Villacampa
PSPrithika Sritharan
Prithika Sritharan
CSClaire Swift
Claire Swift
KDKathryn Dunne
Kathryn Dunne
NTNicholas C. Turner
Nicholas C. Turner
Purpose: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for ctDNA detection is unknown. Experimental Design: The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays for ctDNA molecular residual disease (MRD) detection in early-stage triple-negative breast cancer. We compared tumor-informed dPCR assays with tumor-informed personalized multimutation sequencing assays in 141 patients from cTRAK-TN. Results: MRD was first detected by personalized sequencing in 47.9% of patients, 0% first detected by dPCR, and 52.1% with both assays simultaneously (P < 0.001; Fisher exact test). The median lead time from ctDNA detection to relapse was 6.1 months with personalized sequencing and 3.9 months with dPCR (P = 0.004, mixed-effects Cox model). Detection of MRD at the first time point was associated with a shorter time to relapse compared with detection at subsequent time points (median lead time 4.2 vs. 7.1 months; P = 0.02). Conclusions: Personalized multimutation sequencing assays have potential clinically important improvements in clinical outcome in the early detection of MRD.

29 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ARAlistair Ring
Alistair Ring
LKLucy S. Kilburn
Lucy S. Kilburn
APAlex Pearson
Alex Pearson
LMLaura Moretti
Laura Moretti
AAAngelica Afshari-Mehr
Angelica Afshari-Mehr
NTNicholas C. Turner
Nicholas C. Turner
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC. Patients and Methods: Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300 mg twice a day continuously and celarasertib 160 mg on days 1–7 on a 28-day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were preplanned to identify predictors of response. Results: 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95% confidence interval, 10.4–25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumors with functional homologous recombination deficiency by RAD51 foci. Conclusions: The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy.

16 February 2024
Verified
Other
Open access
MCMaria Coakley
Maria Coakley
GVGuillermo Villacampa
Guillermo Villacampa
PSPrithika Sritharan
Prithika Sritharan
CSClaire Swift
Claire Swift
KDKathryn Dunne
Kathryn Dunne
NTNicholas C. Turner
Nicholas C. Turner
Diagnostic performance of RaDaR assay at 24 months.

16 February 2024
Verified
Other
Open access
MCMaria Coakley
Maria Coakley
GVGuillermo Villacampa
Guillermo Villacampa
PSPrithika Sritharan
Prithika Sritharan
CSClaire Swift
Claire Swift
KDKathryn Dunne
Kathryn Dunne
NTNicholas C. Turner
Nicholas C. Turner
Correlation between the tumor fraction percentage as reported by mean Variant Allele Frequency (mean VAF) or estimated Variant Allele Frequency (eVAF) for the RaDaR ctDNA assay.

16 February 2024
Verified
Other
Open access
MCMaria Coakley
Maria Coakley
GVGuillermo Villacampa
Guillermo Villacampa
PSPrithika Sritharan
Prithika Sritharan
CSClaire Swift
Claire Swift
KDKathryn Dunne
Kathryn Dunne
NTNicholas C. Turner
Nicholas C. Turner
Rate of concordance and discordance between RaDaR and dPCR assays that tracked one or two variants, by sample

16 February 2024
Verified
Other
Open access
MCMaria Coakley
Maria Coakley
GVGuillermo Villacampa
Guillermo Villacampa
PSPrithika Sritharan
Prithika Sritharan
CSClaire Swift
Claire Swift
KDKathryn Dunne
Kathryn Dunne
NTNicholas C. Turner
Nicholas C. Turner
Rate of concordance and discordance between RaDaR and dPCR assays that tracked one or two variants, by sample